Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）
关键词
psoriasis,tildrakizumab,moderate-to-severe
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要